Epigenomics AG
Company Profile
Business description
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
Contact
Geneststrasse 5
BerlinBB10829
DEUT: +49 30243450
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
3
Stocks News & Analysis
stocks
Chart of the Week: Aussie dividend yields are less attractive than alternatives
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,845.60 | 2.50 | 0.03% |
| CAC 40 | 8,086.05 | 20.11 | -0.25% |
| DAX 40 | 23,960.59 | 116.28 | -0.48% |
| Dow JONES (US) | 47,885.97 | 228.29 | -0.47% |
| FTSE 100 | 9,774.32 | 89.53 | 0.92% |
| HKSE | 25,468.78 | 233.37 | 0.92% |
| NASDAQ | 22,693.32 | 418.14 | -1.81% |
| Nikkei 225 | 49,134.63 | 377.65 | -0.76% |
| NZX 50 Index | 13,265.44 | 30.47 | -0.23% |
| S&P 500 | 6,721.43 | 78.83 | -1.16% |
| S&P/ASX 200 | 8,562.50 | 6.00 | 0.07% |
| SSE Composite Index | 3,870.28 | 45.47 | 1.19% |